AbbVie (NYSE:ABBV) Releases FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 13.950-13.990 for the period, compared to the consensus estimate of 13.950. The company issued revenue guidance of $67.8 billion, compared to the consensus revenue estimate of $67.6 billion. AbbVie also updated its Q4 2026 guidance to 3.830-3.870 EPS.

Analyst Ratings Changes

ABBV has been the topic of a number of recent research reports. Guggenheim increased their target price on AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a report on Monday. Bank of America restated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. BMO Capital Markets set a $315.00 price target on shares of AbbVie in a research report on Wednesday. Wells Fargo & Company lifted their price target on AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday. Finally, JPMorgan Chase & Co. lifted their price target on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $297.46.

AbbVie Price Performance

NYSE ABBV opened at $294.15 on Thursday. The stock has a market capitalization of $519.71 billion, a price-to-earnings ratio of 50.63, a PEG ratio of 1.30 and a beta of 0.20. AbbVie has a one year low of $190.75 and a one year high of $298.74. The business’s fifty day moving average is $270.80 and its 200-day moving average is $238.28.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The firm had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the prior year, the firm earned $1.86 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Research analysts expect that AbbVie will post 13.99 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is currently 125.30%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by company insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie beat third-quarter earnings and revenue expectations, reporting $17.4 billion in revenue, and raised its 2026 adjusted EPS outlook to $13.95–$13.99 and revenue guidance to $67.8 billion. The results support the company’s growth case. AbbVie Stock Climbs As Q3 Earnings Fuel Growth Case
• Positive Sentiment: AbbVie licensed global rights to Nxera Pharma’s experimental oral IBD drug NXE0033744, paying $100 million upfront and offering up to $1.37 billion in development and commercial milestones, plus royalties. The candidate could broaden AbbVie’s IBD pipeline, although it remains experimental. AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
• Positive Sentiment: AbbVie expanded its Oxford research facility as part of an investment exceeding £120 million, bolstering UK R&D capacity in immunology, neurology and oncology. AbbVie expands Oxford R&D facility
• Positive Sentiment: Several analysts raised price targets or expressed optimism following the earnings report, adding to favorable sentiment around the results. Morgan Stanley raises AbbVie price target
• Neutral Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 was below the cited $3.89 consensus, while revenue guidance of $18.4 billion was above expectations—an uneven near-term outlook. AbbVie Q3 earnings and outlook
• Negative Sentiment: AbbVie discontinued a Phase 2 solid-tumor drug program after seeing limited benefit, a setback for that portion of its pipeline. The stock’s already strong run and high valuation may also leave less room for disappointment. AbbVie abandons Phase 2 solid tumor drug

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.